Transgene and NEC extend collaboration to develop head and neck cancer vaccine

Transgene and NEC extend collaboration to develop head and neck cancer vaccine

Submitted by admin on January 10, 2024 - 9:20am
Source: 
Biopharma Reporter
News Tags: 
Transgene
NEC
head and neck cancer
clinical trials
TG4050
Headline: 
Transgene and NEC extend collaboration to develop head and neck cancer vaccine
snippet: 

Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.

Do Not Allow Advertisers to Use My Personal information